Gemcitabine--status of preclinical studies and perspectives for future clinical applications of this novel nucleoside analog. Symposium proceedings. Amsterdam, The Netherlands, March 15, 1994.
D000818:Animals; D000964:Antimetabolites, Antineoplastic / Q000627:therapeutic use*; D000971:Antineoplastic Combined Chemotherapy Protocols / Q000494:pharmacology / Q000627:therapeutic use; D003131:Combined Modality Therapy; D004273:DNA, Neoplasm / Q000187:drug effects; D003841:Deoxycytidine / Q000031:analogs & derivatives* / Q000627:therapeutic use; D004347:Drug Interactions; D019008:Drug Resistance, Neoplasm; D006801:Humans; D009369:Neoplasms / Q000188:drug therapy* / Q000532:radiotherapy; D012334:RNA, Neoplasm / Q000187:drug effects; D012264:Ribonucleotide Reductases / Q000037:antagonists & inhibitors* / Q000627:therapeutic use; D014407:Tumor Cells, Cultured / Q000187:drug effects; D000093542:Gemcitabine
D000964:Antimetabolites, Antineoplastic; D004273:DNA, Neoplasm; D012334:RNA, Neoplasm; D003841:Deoxycytidine; D012264:Ribonucleotide Reductases; D000093542:Gemcitabine